Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial

Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

(2013) Mark T. Brown et al.   ARTHRITIS AND RHEUMATISM

Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

(2012) Mark T. Brown et al.   JOURNAL OF PAIN

Efficacy and safety of intravenous tanezumab in osteoarthritis hip and knee pain: comparison to placebo and naproxen in two phase III studies (NCT00830063 & NCT00863304)

(2011) E. Ekman et al.   JOURNAL OF PAIN

Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis

(2011) R.J. Evans et al.   JOURNAL OF UROLOGY

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study

(2011) H. Nagashima et al.   OSTEOARTHRITIS AND CARTILAGE

Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain

(2011) T.J. Schnitzer et al.   OSTEOARTHRITIS AND CARTILAGE

Efficacy and safety of tanezumab in the treatment of chronic low back pain

(2011) Nathaniel Katz et al.   PAIN

Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee

(2010) Nancy E. Lane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Nerve Growth Factor in Pain

(2008) Judy J Watson et al.   BIODRUGS

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

(2008) W. Zhang et al.   OSTEOARTHRITIS AND CARTILAGE

Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors

(2008) Yasmina Noubia Abdiche et al.   PROTEIN SCIENCE